T-Cell Acute Lymphoblastic Leukemia

NCI Definition: Acute lymphoblastic leukemia of T-cell origin. It comprises about 15% of childhood cases and 25% of adult cases. It is more common in males than females. (WHO, 2001) [1]

Clinical Trials

View Clinical Trials for T-Cell Acute Lymphoblastic Leukemia

There are 25 clinical trials for T-cell acute lymphoblastic leukemia, of which 22 are open and 3 are completed or closed. Of the trials that contain T-cell acute lymphoblastic leukemia as an inclusion criterion, 1 is early phase 1 (1 open), 8 are phase 1 (7 open), 5 are phase 1/phase 2 (4 open), 6 are phase 2 (5 open), 3 are phase 2/phase 3 (3 open), and 2 are phase 3 (2 open).

BCR-ABL1, CD7, and t(9;22)(q34;q11) are the most frequent gene inclusion criteria for T-cell acute lymphoblastic leukemia clinical trials [3].

Trials Investigating T-Cell Acute Lymphoblastic Leukemia by Gene and Recruiting Status

Cyclophosphamide, fludarabine, and cytarabine are the most common interventions in T-cell acute lymphoblastic leukemia clinical trials.

Drugs Being Investigated in T-Cell Acute Lymphoblastic Leukemia Trials by Recruiting Status

Significant Genes in T-Cell Acute Lymphoblastic Leukemia

ABL1 +

ABL1 is an inclusion eligibility criterion in 6 clinical trials for T-cell acute lymphoblastic leukemia, of which 5 are open and 1 is closed. Of the trials that contain ABL1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [3].

ABL2 +

ABL2 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ABL2 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

AFF1 +

AFF1 is an inclusion eligibility criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain AFF1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].

ASXL1 +

ASXL1 is an inclusion eligibility criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain ASXL1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

BCR +

BCR is an inclusion eligibility criterion in 6 clinical trials for T-cell acute lymphoblastic leukemia, of which 5 are open and 1 is closed. Of the trials that contain BCR status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [3].

CBL +

CBL is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBL status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CEP72 +

CEP72 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CEP72 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

CRLF2 +

CRLF2 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CRLF2 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

DEK +

DEK is an inclusion eligibility criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain DEK status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

ELL +

ELL is an inclusion eligibility criterion in 2 clinical trials for T-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain ELL status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

EPOR +

EPOR is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains EPOR status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR1 +

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR2 +

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR3 +

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR4 +

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FLT3 +

FLT3 is an inclusion eligibility criterion in 5 clinical trials for T-cell acute lymphoblastic leukemia, of which 5 are open and 0 are closed. Of the trials that contain FLT3 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [3].

IL7R +

IL7R is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IL7R status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

JAK1 +

JAK1 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

JAK2 +

JAK2 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

JAK3 +

JAK3 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

KMT2A +

KMT2A is an inclusion eligibility criterion in 5 clinical trials for T-cell acute lymphoblastic leukemia, of which 5 are open and 0 are closed. Of the trials that contain KMT2A status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].

KRAS +

KRAS is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

LYN +

LYN is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains LYN status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

MECOM +

MECOM is an inclusion eligibility criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain MECOM status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

MLF1 +

MLF1 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLLT1 +

MLLT1 is an inclusion eligibility criterion in 2 clinical trials for T-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MLLT1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MLLT10 +

MLLT10 is an inclusion eligibility criterion in 2 clinical trials for T-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MLLT10 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MLLT3 +

MLLT3 is an inclusion eligibility criterion in 2 clinical trials for T-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MLLT3 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MLLT4 +

MLLT4 is an inclusion eligibility criterion in 2 clinical trials for T-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MLLT4 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

NPM1 +

NPM1 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS +

NRAS is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRIP3 +

NRIP3 is an inclusion eligibility criterion in 2 clinical trials for T-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain NRIP3 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

NTRK1 +

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

NTRK2 +

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

NTRK3 +

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

NUP214 +

NUP214 is an inclusion eligibility criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain NUP214 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

PDGFRB +

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

PTPN11 +

PTPN11 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTPN11 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain RPN1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

RUNX1 +

RUNX1 is an inclusion eligibility criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain RUNX1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

SH2B3 +

SH2B3 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SH2B3 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

TP53 +

TP53 is an inclusion eligibility criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain TP53 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

TYK2 +

TYK2 is an inclusion eligibility criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TYK2 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

Disease Details

Synonyms

Bone marrow leukemia T cell acute (T-ALL)

Parent(s)

T-Cell Lymphoblastic Leukemia/Lymphoma

Children

Adult T-Cell Acute Lymphoblastic Leukemia and Early T-Cell Acute Lymphoblastic Leukemia

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

T-Cell Acute Lymphoblastic Leukemia

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in T-Cell Acute Lymphoblastic Leukemia

Disease Details

References

About

Molecular Medicine

Content Types